Although the PCA3 biomarker's potential in some diagnostic circumstances is encouraging, PCA3 as a stand‐alone test usually leads to a high rate of underdiagnosis of high‐grade PCa disease. This evidence concerns the gene PCA3 and posterior cortical atrophy.